{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:14:14Z","timestamp":1768778054027,"version":"3.49.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Decreased arylesterase (ArylE) activity of paraoxonase-1, a HDL-associated protein with anti-inflammatory and antioxidant properties, has been associated with increased risk of cardiac events in patients with ischaemic heart failure (HF). We aim to investigate the prognostic significance of changes in serum ArylE activity over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We examined the association between baseline and follow-up serum ArylE activity and HF outcomes (death, cardiac transplantation, or ventricular assist device implantation) in 299 patients with HF enrolled in a prospective cohort study from January 2008 to July 2009, with 145 patients having available follow-up levels at 1 year. A significant drop in ArylE activity on follow-up was defined as a drop of \u226525% vs. baseline levels. Mean baseline and follow-up ArylE activity levels were 110.6 \u00b1 29.9 \u00b5mol\/min\/mL and 106.2 \u00b1 29.9 \u00b5mol\/min\/mL, respectively. After a mean follow-up of 2.8 \u00b1 1.1 years, low baseline ArylE activity was associated with increased risk of adverse HF events [hazard ratio (HR; lowest vs highest tertile) 2.6, 95% confidence interval (CI) 1.3\u20135.5, P = 0.01] and HF-related hospitalization [incidence rate ratio (lowest vs. highest tertile) 2.1, 95% CI 1.2\u20134.1, P = 0.016], which remained significant after adjustment for age, male gender, systolic blood pressure, diabetes, creatinine clearance, CAD, and HDL-cholesterol levels. Patients who had a significant drop in ArylE activity on follow-up (n = 18) had a significantly increased risk of HF events (HR 4.9, 95% CI 1.6\u201314.6, P = 0.005), even after adjustment for baseline levels of ArylE activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reduced baseline ArylE activity and decreased levels on follow-up are associated with adverse outcomes in stable outpatients with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.777","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T00:00:45Z","timestamp":1486512045000},"page":"748-755","source":"Crossref","is-referenced-by-count":31,"title":["High-Density Lipoprotein-Associated Paraoxonase-1 Activity for Prediction of Adverse Outcomes in Outpatients with Chronic Heart Failure"],"prefix":"10.1093","volume":"19","author":[{"given":"Muhammad","family":"Hammadah","sequence":"first","affiliation":[{"name":"Division of Cardiology, Emory University , Atlanta, GA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas P.","family":"Kalogeropoulos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Emory University , Atlanta, GA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki V.","family":"Georgiopoulou","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Emory University , Atlanta, GA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malory","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Mathematics, Cleveland State University , Cleveland, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley L.","family":"Hazen","sequence":"additional","affiliation":[{"name":"Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic , Cleveland, OH ,","place":["USA"]},{"name":"Department of Cardiovascular Medicine, Heart and Vascular Institute , Cleveland Clinic, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stony Brook University , Stony Brook, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic , Cleveland, OH ,","place":["USA"]},{"name":"Department of Cardiovascular Medicine, Heart and Vascular Institute , Cleveland Clinic, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"2026011721185002900_ejhf777-bib-0001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/res.89.3.198","article-title":"Oxidative stress and apoptosis in heart failure progression","volume":"89","author":"Hare","year":"2001","journal-title":"Circ Res"},{"key":"2026011721185002900_ejhf777-bib-0003","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/ATVBAHA.112.253930","article-title":"Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk","volume":"32","author":"Tang","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026011721185002900_ejhf777-bib-0004","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa0807265","article-title":"Racial differences in incident heart failure among young adults","volume":"360","author":"Bibbins-Domingo","year":"2009","journal-title":"N Engl J Med"},{"key":"2026011721185002900_ejhf777-bib-0005","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/CIRCULATIONAHA.109.830984","article-title":"Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study","volume":"120","author":"Velagaleti","year":"2009","journal-title":"Circulation"},{"key":"2026011721185002900_ejhf777-bib-0006","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1172\/JCI67478","article-title":"Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex","volume":"123","author":"Huang","year":"2013","journal-title":"J Clin Invest"},{"key":"2026011721185002900_ejhf777-bib-0007","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0269881107077609","article-title":"Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment","volume":"21","author":"Sarandol","year":"2007","journal-title":"J Psychopharmacol"},{"key":"2026011721185002900_ejhf777-bib-0008","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCHEARTFAILURE.110.958348","article-title":"Diminished anti-oxidant activity of high-density lipoprotein-associated proteins in systolic heart failure","volume":"4","author":"Wilson Tang","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011721185002900_ejhf777-bib-0009","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.112.110536","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations","volume":"126","author":"Rogers","year":"2012","journal-title":"Circulation"},{"key":"2026011721185002900_ejhf777-bib-0010","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1016\/j.csda.2008.04.009","article-title":"Comparison of the Andersen\u2013Gill model with Poisson and negative binomial regression on recurrent event data","volume":"52","author":"Jahn-Eimermacher","year":"2008","journal-title":"Comput Stat Data Anal"},{"key":"2026011721185002900_ejhf777-bib-0011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijcard.2014.11.018","article-title":"Reactive oxidative metabolites are associated with the severity of heart failure and predict future cardiovascular events in heart failure with preserved left ventricular ejection fraction","volume":"179","author":"Hirata","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0012","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","article-title":"Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD)","volume":"27","author":"Torre-Amione","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0013","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/oxfordjournals.eurheartj.a015142","article-title":"Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure","volume":"18","author":"Lommi","year":"1997","journal-title":"Eur Heart J"},{"key":"2026011721185002900_ejhf777-bib-0014","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1089\/ars.2009.2524","article-title":"Autophagy, redox signaling, and ventricular remodeling","volume":"11","author":"Gurusamy","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"2026011721185002900_ejhf777-bib-0015","doi-asserted-by":"crossref","first-page":"30d","DOI":"10.1016\/j.amjcard.2008.02.005","article-title":"The role of leukocyte-generated oxidants in left ventricular remodeling","volume":"101","author":"Penn","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0016","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/eurheartj\/ehn360","article-title":"Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure","volume":"29","author":"Tang","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011721185002900_ejhf777-bib-0017","doi-asserted-by":"crossref","first-page":"H651","DOI":"10.1152\/ajpheart.00638.2014","article-title":"Cardiomyocyte mitochondrial oxidative stress and cytoskeletal breakdown in the heart with a primary volume overload","volume":"308","author":"Yancey","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721185002900_ejhf777-bib-0018","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1161\/hq0901.094247","article-title":"Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?","volume":"21","author":"Mackness","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026011721185002900_ejhf777-bib-0019","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2015.06.004","article-title":"Paraoxonase-1 and oxidized lipoprotein lipids. The Cardiovascular Risk in Young Finns Study","volume":"241","author":"Kresanov","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026011721185002900_ejhf777-bib-0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MCA.0b013e328309b9f0","article-title":"Association of paraoxonase activity and coronary collateral flow","volume":"19","author":"Yildiz","year":"2008","journal-title":"Coron Artery Dis"},{"key":"2026011721185002900_ejhf777-bib-0021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1096\/fj.09-144410","article-title":"Paraoxonase 1 protects against protein N-homocysteinylation in humans","volume":"24","author":"Perla-Kajan","year":"2010","journal-title":"FASEB J"},{"key":"2026011721185002900_ejhf777-bib-0022","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2005.03.030","article-title":"Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease","volume":"183","author":"Pasqualini","year":"2005","journal-title":"Atherosclerosis"},{"key":"2026011721185002900_ejhf777-bib-0023","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000070954.00271.13","article-title":"Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study","volume":"107","author":"Mackness","year":"2003","journal-title":"Circulation"},{"key":"2026011721185002900_ejhf777-bib-0024","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/j.jacc.2006.01.074","article-title":"Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease","volume":"47","author":"Graner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"JAMA"},{"key":"2026011721185002900_ejhf777-bib-0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006809","article-title":"Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study","volume":"4","author":"Birjmohun","year":"2009","journal-title":"PLoS One"},{"key":"2026011721185002900_ejhf777-bib-0027","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jmg.2004.029850","article-title":"Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study","volume":"42","author":"Burdon","year":"2005","journal-title":"J Med Genet"},{"key":"2026011721185002900_ejhf777-bib-0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1155\/2012\/953768","article-title":"Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study","volume":"33","author":"Mackness","year":"2012","journal-title":"Dis Markers"},{"key":"2026011721185002900_ejhf777-bib-0029","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1373\/clinchem.2007.099044","article-title":"Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study","volume":"54","author":"Thyagarajan","year":"2008","journal-title":"Clin Chem"},{"key":"2026011721185002900_ejhf777-bib-0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3906\/sag-1311-91","article-title":"The effects of atorvastatin on antioxidant\/antiinflammatory properties of HDLs in hypercholesterolemics","volume":"45","author":"Akalin Ciftci","year":"2015","journal-title":"Turk J Med Sci"},{"key":"2026011721185002900_ejhf777-bib-0031","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2125.2008.03213.x","article-title":"The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters","volume":"66","author":"Mirdamadi","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2026011721185002900_ejhf777-bib-0032","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/01.ATV.20.9.2113","article-title":"Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients","volume":"20","author":"Tomas","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026011721185002900_ejhf777-bib-0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10557-007-6027-1","article-title":"Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment?","volume":"21","author":"Thomson","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026011721185002900_ejhf777-bib-0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)09328-5","article-title":"Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026011721185002900_ejhf777-bib-0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.293.11.1338","article-title":"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial","volume":"293","author":"Lonn","year":"2005","journal-title":"JAMA"},{"key":"2026011721185002900_ejhf777-bib-0036","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa060900","article-title":"Homocysteine lowering with folic acid and B vitamins in vascular disease","volume":"354","author":"Lonn","year":"2006","journal-title":"N Engl J Med"},{"key":"2026011721185002900_ejhf777-bib-0037","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026011721185002900_ejhf777-bib-0038","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026011721185002900_ejhf777-bib-0039","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20021426","article-title":"Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction","volume":"197","author":"Askari","year":"2003","journal-title":"J Exp Med"},{"key":"2026011721185002900_ejhf777-bib-0040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure","volume":"98","author":"Tang","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0041","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.cardfail.2014.08.001","article-title":"Prognostic value of elevated serum ceruloplasmin levels in patients with heart failure","volume":"20","author":"Hammadah","year":"2014","journal-title":"J Card Fail"},{"key":"2026011721185002900_ejhf777-bib-0042","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002115","article-title":"Elevated soluble Fms-like tyrosine kinase-1 and placental-like growth factor levels are associated with development and mortality risk in heart failure","volume":"9","author":"Hammadah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026011721185002900_ejhf777-bib-0043","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0735-1097(01)01790-9","article-title":"Pressure overload hypertrophy and congestive heart failure. Where is the \u2018Achilles\u2019 heel'?","volume":"39","author":"Peterson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011721185002900_ejhf777-bib-0044","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.2174\/1381612822666160701073452","article-title":"Lipids, statins and heart failure: an update","volume":"22","author":"Katsiki","year":"2016","journal-title":"Curr Pharm Des"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/6\/748\/66328286\/eurjhf_19_6_748.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/6\/748\/66328286\/eurjhf_19_6_748.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:20:26Z","timestamp":1768702826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/6\/748\/8418601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,2,7]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.777","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,2,7]]}}}